| Head and Neck Neoplasms |
NCT03017053: The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor |
|
|
| Recruiting | 4 | 270 | RoW | Radiotherapy, Elective neck dissection | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Oral Cancer | 07/25 | 07/25 | | |
NCT01884623: Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer |
|
|
| Completed | 3 | 82 | Europe | Cetuximab, Methotrexate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Ligue contre le cancer, France, Merck Serono International SA | Head Neck Cancer Squamous Cell Recurrent | 10/21 | 10/21 | | |
NCT01141231: Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer |
|
|
| Active, not recruiting | 3 | 240 | US | Acupuncture | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Oral Complications of Chemotherapy and Head/Neck Radiation, Radiation Toxicity, Xerostomia | 11/19 | 11/20 | | |
NCT02363400: A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA |
|
|
| Enrolling by invitation | 3 | 147 | RoW | MEP, epirubicin, cisplatin, oral Tegafur-uracil, mitomycin-C | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Mackay Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Veterans General Hospital., Taichung Veterans General Hospital | Nasopharyngeal Carcinoma | 12/19 | 12/22 | | |
NCT02461043: Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 386 | RoW | paclitaxel; cisplatin, radiation | Chinese Academy of Medical Sciences | Esophageal Cancer | 12/20 | 12/23 | | |
NCT02621970: Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 3 | 534 | RoW | Cisplatin 1, DDP, Cisplatin 2, Docetaxel, T, Xeloda, X, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University | Nasopharyngeal Carcinoma | 01/22 | 01/24 | | |
NCT02610010: Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 462 | RoW | Cisplatin, DDP, Intensity-modulated radiotherapy | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University | Nasopharyngeal Carcinoma | 11/22 | 11/25 | | |
IRCNPC, NCT03015727: Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 440 | RoW | Docetaxel, DOC, Cisplatin, DDP, IMRT/TOMO, Chemotherapy, concurrent chemotherapy | Zhejiang Cancer Hospital, Zhejiang Provincial People's Hospital, The Central Hospital of Lishui City, Jinhua Central Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Eastern Hospital, People's Hospital of Quzhou | Locally Advanced Nasopharyngeal Carcinoma | 12/22 | 12/24 | | |
NCT02633176: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 120 | RoW | Cetuximab, Erbitux, Cisplatin, Docetaxel, Taxotere, Capecitabine, Xeloda, Radiotherapy | Sun Yat-sen University, Chinese Southwest Oncology Group | Nasopharyngeal Carcinoma | 01/23 | | | |
| Recruiting | 3 | 270 | Europe | Radiotherapy, IMRT-SIB | Technische Universität München | Locally Advanced Head and Neck Cancer | 01/25 | 09/25 | | |
| Recruiting | 2/3 | 584 | Europe | Carboplatin, Paclitaxel, Cisplatin, Capecitabine, Radiotherapy | Lisette Nixon, Cancer Research UK | Oesophageal Cancer | 04/21 | 04/23 | | |
NCT02923258: Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer |
|
|
| Completed | 2/3 | 224 | RoW | Docetaxel, Cisplatin, IMRT | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Fudan University | Oral Cavity Squamous Cell Carcinoma | 02/22 | 04/23 | | |
| Recruiting | 2 | 90 | Europe | radiochemotherapy with 70 Gy, radiochemotherapy with 77 Gy | University Hospital Tuebingen | Squamous Cell Carcinoma of the Head and Neck | 12/17 | 12/22 | | |
NCT03076281: Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery |
|
|
| Active, not recruiting | 2 | 7 | US | Metformin Hydrochloride, 1,1-Dimethylbiguanide Hydrochloride, 1115-70-4, 91485, Cidophage, Dimefor, Glucoformin, Glucophage, Glifage, Doxycycline, 17086-28-1, Doxycycline Monohydrate, Metformin +Doxycycline | Sidney Kimmel Cancer Center at Thomas Jefferson University | Larynx, LIP, Oral Cavity, Pharynx | 12/18 | 08/20 | | |
| Recruiting | 2 | 10 | Europe | Pimonidazole, Oral Hypoxyprobe | Marius Gustav Bredell | Head and Neck Cancer | 10/22 | 10/22 | | |
NCT03047265: Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2 | 164 | RoW | Paclitaxel, TAXOL, Cisplatin, DDP | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/25 | 06/27 | | |
NCT02490735: CIK in Treating Patients With Esophageal Cancer |
|
|
| Not yet recruiting | 2 | 2000 | RoW | Cytokine-induced Killer Cells, CIK | The First People's Hospital of Changzhou | Esophageal Squamous Cell Carcinoma | 08/40 | 08/42 | | |
| Not yet recruiting | 1/2 | 69 | NA | Durvalumab, Cetuximab, Intensity modulated radiation therapy (IMRT) | Azienda Ospedaliero-Universitaria Careggi | Head and Neck Neoplasms | 01/22 | 01/25 | | |
NCT01860430: A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer |
|
|
| Active, not recruiting | 1 | 18 | US | Cetuximab/IMRT Plus Ipilimumab | Robert Ferris, National Cancer Institute (NCI) | Cancer of Head and Neck | 07/16 | 03/18 | | |
FAITH, NCT02519959: Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer |
|
|
| Not yet recruiting | 1 | 10 | Canada | (F18)-FAZA injection, Pimonidazole-HCl, Oral HypoxyprobeTM-1 | Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Cancer Care Ontario, University of Western Ontario, Canada, Princess Margaret Hospital, Canada | Cancer of the Tongue | 12/17 | 12/18 | | |
| Active, not recruiting | N/A | 650 | US | | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Barrett's Esophagus, Esophageal Neoplasm | | | | |
NCT02937467: The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules |
|
|
| Available | N/A | | RoW | SWE | Peking University Cancer Hospital & Institute, Shanghai 10th People's Hospital | Thyroid Nodules | 12/17 | 12/18 | | |
NCT02211677: Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 720 | RoW | | Sun Yat-sen University | Nasopharyngeal Neoplasms, Blood Cell Count, Neoplasm Staging, Prognosis | 12/19 | 12/24 | | |
| Active, not recruiting | N/A | 12000 | NA | Capsule sponge | Tehran University of Medical Sciences, National Cancer Institute (NCI), International Agency for Research on Cancer, University of Cambridge, Golestan University of Medical Science | Esophageal Cancer | 12/20 | 12/23 | | |
| Active, not recruiting | N/A | 33948 | RoW | Endoscopic Screening | Peking University | Esophageal Squamous Cell Carcinoma, Dysplasia | 12/22 | 12/27 | | |
NCT00574327: Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry |
|
|
| Recruiting | N/A | 3000 | US | | Midwest Biomedical Research Foundation, Kansas City Veteran Affairs Medical Center | Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma | 10/28 | 01/29 | | |
NCT02869620: Institut Paoli Calmettes Thyroid Cancer Database |
|
|
| Recruiting | N/A | 3000 | Europe | Data collection | Institut Paoli-Calmettes | Thyroid Neoplasms | 01/30 | 12/30 | | |
| Recruiting | N/A | 10000 | Europe | Radiotherapy, Chemoradiation | University Medical Center Groningen | Esophageal Cancer | 01/30 | 01/30 | | |